These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 24189358)

  • 1. Seroconversion of hepatitis B envelope antigen by entecavir in a child with hepatitis B virus-related membranous nephropathy.
    Igarashi T; Shimizu A; Igarashi T; Hanaoka K; Yoshizaki K; Shigemori T; Shimizu S; Komeichi H; Itoh Y
    J Nippon Med Sch; 2013; 80(5):387-95. PubMed ID: 24189358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful Use of Entecavir in Hepatitis B-associated Membranous Nephropathy.
    Mahajan V; D'Cruz S; Nada R; Sachdev A
    J Trop Pediatr; 2018 Jun; 64(3):249-252. PubMed ID: 28977667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of occult hepatitis B virus infection related membranous nephropathy after entecavir therapy.
    Xiong QF; Zhong YD; Hu ZL; Yang YF
    Acta Clin Belg; 2015 Jun; 70(3):223-5. PubMed ID: 25510219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of entecavir in treating hepatitis B virus-associated membranous nephropathy.
    Wang L; Xie B; Zheng Q; Xu L; Ye Z
    Rev Esp Enferm Dig; 2020 Nov; 112(11):843-849. PubMed ID: 33054304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
    Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B virus-related membranous nephropathy treated with entecavir.
    Ikee R; Ishioka K; Oka M; Maesato K; Moriya H; Hidaka S; Ohtake T; Kobayashi S
    Nephrology (Carlton); 2010 Mar; 15(2):266. PubMed ID: 20470290
    [No Abstract]   [Full Text] [Related]  

  • 8. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
    Chang TT; Gish RG; de Man R; Gadano A; Sollano J; Chao YC; Lok AS; Han KH; Goodman Z; Zhu J; Cross A; DeHertogh D; Wilber R; Colonno R; Apelian D;
    N Engl J Med; 2006 Mar; 354(10):1001-10. PubMed ID: 16525137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
    Fong TL; Tien A; Jo KJ; Chu D; Cheung E; Mena EA; Phan QQ; Yu AS; Mohammed W; Velasco A; LeDuc VH; Nguyen N; Han SB; Chang M; Bae HS; Cho YW; Tong MJ; Cooper SL
    Dig Dis Sci; 2015 Nov; 60(11):3465-72. PubMed ID: 26138653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete remission of hepatitis B virus-related membranous nephropathy after entecavir monotherapy.
    Yang YF; Xiong QF; Zhao W; Zhong YD
    Clin Res Hepatol Gastroenterol; 2012 Oct; 36(5):e89-92. PubMed ID: 22572521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.
    Yuan Y; Iloeje UH; Hay J; Saab S
    J Manag Care Pharm; 2008; 14(1):21-33. PubMed ID: 18240879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience of anti-viral therapy in hepatitis B-associated membranous nephropathy, including Lamivudine-resistant strains.
    Sun IO; Hong YA; Park HS; Choi SR; Chung BH; Park CW; Yang CW; Kim YS; Choi BS
    Korean J Intern Med; 2012 Dec; 27(4):411-6. PubMed ID: 23269882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy.
    Huang YW; Takahashi S; Tsuge M; Chen CL; Wang TC; Abe H; Hu JT; Chen DS; Yang SS; Chayama K; Kao JH
    Antivir Ther; 2015; 20(4):369-75. PubMed ID: 24739420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
    Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
    Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
    Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of entecavir on hepatitis B virus covalently closed circular DNA in hepatitis B e antigen-positive patients with hepatitis B.
    Shi M; Sun WL; Hua YY; Han B; Shi L
    PLoS One; 2015; 10(2):e0117741. PubMed ID: 25647607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.
    Sherman M; Yurdaydin C; Simsek H; Silva M; Liaw YF; Rustgi VK; Sette H; Tsai N; Tenney DJ; Vaughan J; Kreter B; Hindes R;
    Hepatology; 2008 Jul; 48(1):99-108. PubMed ID: 18537189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.
    Leung N; Peng CY; Hann HW; Sollano J; Lao-Tan J; Hsu CW; Lesmana L; Yuen MF; Jeffers L; Sherman M; Min A; Mencarini K; Diva U; Cross A; Wilber R; Lopez-Talavera J
    Hepatology; 2009 Jan; 49(1):72-9. PubMed ID: 19065670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early hepatitis B viral DNA clearance predicts treatment response at week 96.
    Fu XY; Tan DM; Liu CM; Gu B; Hu LH; Peng ZT; Chen B; Xie YL; Gong HY; Hu XX; Yao LH; Xu XP; Fu ZY; He LQ; Li SH; Long YZ; Li DH; Gu JL; Peng SF
    World J Gastroenterol; 2017 Apr; 23(16):2978-2986. PubMed ID: 28522916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
    Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
    Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.